keyword
MENU ▼
Read by QxMD icon Read
search

Five year survival rate

keyword
https://www.readbyqxmd.com/read/28214485/outcome-of-peripheral-venous-reconstructions-during-tumor-resection
#1
Philip Y Sun, Mark D Fleming, Kendall Stauffer, Manju Kalra, Gustavo Oderich, Thomas Bower, Peter Gloviczki, Randall R DeMartino
OBJECTIVE: Peripheral venous reconstruction surgery may be necessary for appropriate oncologic resection; however, the operative approach and surgical outcomes are not well described. We report our experience with these complex reconstructions to identify best practice. METHODS: We retrospectively reviewed all adult patients who underwent peripheral vein reconstruction for tumor resection at Mayo Clinic, Rochester (2000-2015). Patients were classified into three subgroups by the location: iliac (IL), lower extremity (LE), and upper extremity (UE)...
March 2017: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://www.readbyqxmd.com/read/28214261/chemotherapy-in-primary-osteogenic-sarcoma-in-patients-over-the-age-of-forty
#2
Bulent Ozkurt, Kerem Basarir, Bulent Yalcin, Abdullah Merter, Yusuf Yildiz, Yener Saglik
OBJECTIVE: In this study, we sought to review the clinical and histopathological features and the chemotherapy regimens in osteogenic sarcoma in patients over 40 years of age, and we aimed at identifying the possible prognostic factors in this particular group of patients. METHODS: We reviewed 287 patients with osteosarcoma treated between the year 1986 and 2010. Patients from this group who met the following criteria were considered eligible for our study; presence of primary OS, had typical histological and radiographic features of OS, no prior history of cancer or any treatment elsewhere and no prior history of preexisting bone abnormalities...
February 14, 2017: Acta Orthopaedica et Traumatologica Turcica
https://www.readbyqxmd.com/read/28213388/effects-of-dopamine-donor-pretreatment-on-graft-survival-after-kidney-transplantation-a-randomized-trial
#3
Peter Schnuelle, Wilhelm H Schmitt, Christel Weiss, Antje Habicht, Lutz Renders, Martin Zeier, Felix Drüschler, Katharina Heller, Przemyslaw Pisarski, Bernhard Banas, Bernhard K Krämer, Matthias Jung, Kai Lopau, Christoph J Olbricht, Horst Weihprecht, Peter Schenker, Johan W De Fijter, Benito A Yard, Urs Benck
BACKGROUND AND OBJECTIVES: Donor dopamine improves initial graft function after kidney transplantation due to antioxidant properties. We investigated if a 4 µg/kg per minute continuous dopamine infusion administered after brain-death confirmation affects long-term graft survival and examined the exposure-response relationship with treatment duration. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five-year follow-up of 487 renal transplant patients from 60 European centers who had participated in the randomized, multicenter trial of dopamine donor pretreatment between 2004 and 2007 (ClinicalTrials...
February 17, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28213006/a-prospective-multi-institutional-phase-ii-study-of-induction-chemoradiotherapy-followed-by-surgery-in-patients-with-non-small-cell-lung-cancer-involving-the-chest-wall-cjlsg0801
#4
Koji Kawaguchi, Kohei Yokoi, Hiroshi Niwa, Yasuhisa Ohde, Shoichi Mori, Sakae Okumura, Satoshi Shiono, Hiroyuki Ito, Motoki Yano, Kikuo Shigemitsu, Yoshinori Hiramatsu, Jiro Okami, Hideo Saka
OBJECTIVES: The standard therapy for patients with T3N0-1M0 non-small cell lung cancer (NSCLC) involving the chest wall is considered surgical resection and adjuvant therapy. However, the compliance of adjuvant therapy is relatively low, and the prognosis for those patients has been unsatisfactory. Therefore, we conducted a phase II study of induction chemoradiotherapy followed by surgery with the aim of improving the survival. PATIENTS AND METHODS: This treatment strategy consisted of induction chemotherapy (two cycles of cisplatin at 80mg/m(2) on Day 1 and vinorelbine at 20mg/m(2) on Days 1 and 8) concurrent with radiotherapy (40Gy in 20 fractions) followed by surgery...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28211162/efficacy-of-the-oral-mtorc1-inhibitor-everolimus-in-relapsed-or-refractory-indolent-lymphoma
#5
N Nora Bennani, Betsy R LaPlant, Stephen M Ansell, Thomas M Habermann, David J Inwards, Ivana N Micallef, Patrick B Johnston, Luis F Porrata, Joseph P Colgan, Svetomir N Markovic, Grzegorz S Nowakowski, William R Macon, Craig B Reeder, Joseph R Mikhael, Donald W Northfelt, Irene M Ghobrial, Thomas E Witzig
Relapsed indolent lymphoma often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the PI3K/mTOR pathway in several types of lymphoma has shown preclinical and clinical efficacy providing the rationale to test this strategy in the treatment of relapsed/refractory indolent lymphomas. We investigated in a phase II open label clinical trial the efficacy and safety of single agent everolimus, an inhibitor of mTORC1, in patients with relapsed/refractory indolent lymphomas...
February 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28211054/real-world-use-of-pomalidomide-and-dexamethasone-in-double-refractory-multiple-myeloma-suggests-benefit-in-renal-impairment-and-adverse-genetics-a-multi-centre-uk-experience
#6
Nicola Maciocia, Andrew Melville, Simon Cheesman, Faye Sharpley, Karthik Ramasamy, Matthew Streetly, Matthew Jenner, Reuben Benjamin, Steve Schey, Paul Maciocia, Rakesh Popat, Shirley D'sa, Ali Rismani, Aviva Cerner, Kwee Yong, Neil Rabin
Myeloma patients who become refractory to immunomodulatory agents (IMiDs) and bortezomib have poor survival, with limited therapeutic options. Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce. We retrospectively analysed all patients treated with pomalidomide at five UK centres between 2013 and 2016. Of 85 patients identified, 70 had sufficient information for response assessments. Median age was 66 years [40-89], 96·5% were refractory to IMiDs, 72·9% were refractory to both an IMiD and bortezomib and 92·9% were refractory to their last treatment...
February 17, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28210088/clinicopathological-treatment-and-prognosis-study-of-43-gastric-neuroendocrine-carcinomas
#7
De-Jun Liu, Xue-Liang Fu, Wei Liu, Lu-Ying Zheng, Jun-Feng Zhang, Yan-Miao Huo, Jiao Li, Rong Hua, Qiang Liu, Yong-Wei Sun
AIM: To provide more information and therapeutic methods about gastric neuroendocrine carcinomas (G-NECs) which occur rarely but are highly malignant and clinically challenging. METHODS: We retrospectively analyzed the clinicopathological characteristics, treatments, and prognosis of 43 G-NEC patients at our hospital between January 2007 and December 2014. The diagnosis was based on the 2010 World Health Organization criteria. RESULTS: Forty-three G-NECs containing 39 small cell carcinomas and 4 large cell NECs with Ki67 > 60% were included in this study, accounting for only 0...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28209745/platinum-fluoropyrimidine-and-paclitaxel-based-chemotherapy-in-the-treatment-of-advanced-anal-cancer-patients
#8
Francesco Sclafani, Federica Morano, David Cunningham, Chiara Baratelli, Eleftheria Kalaitzaki, David Watkins, Naureen Starling, Ian Chau, Sheela Rao
BACKGROUND: Although treatment of localized anal cancer (AC) is well established, very little evidence is available to inform the management of advanced tumors, and the prognosis of these patients remains poor. We have analyzed treatment pathways and outcomes of a single-institution series of advanced AC patients in order to provide insight into the management of this rare condition. MATERIALS AND METHODS: Inclusion criteria included epidermoid histology, inoperable locally recurrent or metastatic disease, and availability of full medical records...
February 16, 2017: Oncologist
https://www.readbyqxmd.com/read/28209216/hypertrophic-cardiomyopathy-with-left%C3%A2-ventricular-apical-aneurysm-implications-for-risk-stratification-and-management
#9
Ethan J Rowin, Barry J Maron, Tammy S Haas, Ross F Garberich, Weijia Wang, Mark S Link, Martin S Maron
BACKGROUND: A previously under-recognized subset of hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) apical aneurysms is being identified with increasing frequency. However, risks associated with this subgroup are unknown. OBJECTIVES: The authors aimed to clarify clinical course and prognosis of a large cohort of HCM patients with LV apical aneurysms over long-term follow-up. METHODS: The authors retrospectively analyzed 1,940 consecutive HCM patients at 2 centers, 93 of which (4...
February 21, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28207726/long-term-survival-following-diabetic-vitrectomy
#10
Bia Z Kim, Kuo-Luong Lee, Stephen J Guest, David Worsley
AIM: To update long-term survival data on patients with proliferative diabetic retinopathy undergoing vitrectomy and to identify associated risk factors. METHODS: Retrospective clinical record review at a single New Zealand tertiary referral centre. A total of 182 eyes that underwent a vitrectomy for a diabetic vitreous haemorrhage and/or tractional retinal detachment between March 2000 and December 2010 were included. Kaplan-Meier survival curves and Cox-regression analyses were performed for survival rates and associated risk factors...
February 17, 2017: New Zealand Medical Journal
https://www.readbyqxmd.com/read/28207291/small-numbers-big-challenges-adolescent-and-young-adult-cancer-incidence-and-survival-in-new-zealand
#11
Kirsten R Ballantine, Heidi Watson, Scott Macfarlane, Mark Winstanley, Robin P Corbett, Ruth Spearing, Vladimir Stevanovic, Ma Yi, Michael J Sullivan
PURPOSE: This study was undertaken to determine cancer survival and describe the unique spectrum of cancers diagnosed among New Zealand's adolescents and young adult (AYA) population. METHODS: Registrations for 1606 15-24 year olds diagnosed with a new primary malignant tumor between 2000 and 2009 were obtained from the New Zealand Cancer Registry and classified according to AYA diagnostic group and subgroup, age, sex, and prioritized ethnicity. Age-standardized incidence rates (IRs) per million person years and 5-year relative survival ratios were calculated...
February 16, 2017: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/28206975/long-term-clinical-outcomes-of-hematopoietic-cell-transplantation-for-intermediate-to-poor-risk-acute-myeloid-leukemia-during-first-remission-according-to-available-donor-types
#12
Jae-Ho Yoon, Hee-Je Kim, Sung-Soo Park, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min
Standard therapy for acute myeloid leukemia (AML) consists of hematopoietic cell transplantation (HCT) including autologous-HCT (AUTO) and allogeneic-HCT from a matched-sibling donor (MSD) or well-matched unrelated donor (WM-URD). When a conventional donor is not available, HCT from a partially-matched (PM)-URD or familial-mismatched donor (FMMD) is typically considered. We analyzed 561 patients with intermediate to poor-risk molecular cytogenetics who underwent transplant from 2002 to 2013 in their first remission...
February 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28205044/clinical-tumor-stage-is-the-most-important-predictor-of-pathological-complete-response-rate-after-neoadjuvant-chemotherapy-in-breast-cancer-patients
#13
Briete Goorts, Thiemo J A van Nijnatten, Linda de Munck, Martine Moossdorff, Esther M Heuts, Maaike de Boer, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: Pathological complete response (pCR) is the ultimate response in breast cancer patients treated with neoadjuvant chemotherapy (NCT). It might be a surrogate outcome for disease-free survival (DFS) and overall survival (OS). We studied the effect of clinical tumor stage (cT-stage) on tumor pCR and the effect of pCR per cT-stage on 5-year OS and DFS. METHODS: Using the Netherlands Cancer Registry, all primary invasive breast cancer patients treated with NCT from 2005 until 2008 were identified...
February 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28204851/improved-outcomes-for-hepatic-trauma-in-england-and-wales-over-a-decade-of-trauma-and-hepatobiliary-surgery-centralisation
#14
J Barrie, S Jamdar, M F Iniguez, O Bouamra, T Jenks, F Lecky, D A O'Reilly
BACKGROUND: Over the last decade trauma services have undergone a reconfiguration in England and Wales. The objective is to describe the epidemiology, management and outcomes for liver trauma over this period and examine factors predicting survival. METHODS: Patients sustaining hepatic trauma were identified using the Trauma Audit and Research Network database. Demographics, management and outcomes were assessed between January 2005 and December 2014 and analysed over five, 2-year study periods...
February 16, 2017: European Journal of Trauma and Emergency Surgery: Official Publication of the European Trauma Society
https://www.readbyqxmd.com/read/28203299/multi-institutional-prospective-study-of-nedaplatin-plus-s-1-chemotherapy-in-recurrent-and-metastatic-nasopharyngeal-carcinoma-patients-after-failure-of-platinum-containing-regimens
#15
Pei-Jian Peng, Bao-Jun Lv, Zhi-Hui Wang, Hai Liao, Yu-Meng Liu, Zhong Lin, Yun-Yan Con, Pei-Yu Huang
BACKGROUND: In this multi-institutional prospective study, we aimed to assess the safety and efficacy of nedaplatin plus S-1 (NS) chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when platinum-containing regimens failed. METHODS: A total of 52 recurrent and metastatic NPC patients who previously received, but failed with platinum-containing chemotherapy, had oral S-1 chemotherapy (twice daily from the first day to the fourteenth day) and nedaplatin (80 mg/ m(2), day 1) every 3 weeks...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28199742/genetic-analysis-and-clinicopathological-features-of-alk-rearranged-renal-cell-carcinoma-in-a-large-series-of-resected-chinese-renal-cell-carcinoma-patients-and-literature-review
#16
Wenjuan Yu, Yuewei Wang, Yanxia Jiang, Wei Zhang, Yujun Li
AIMS: Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (RCC) is a rare subtype of RCC reported in recent years with 8 cases so far. The present study is focused on screening ALK-rearranged cases from a large cohort of RCCs in China to determine the frequency of ALK rearrangement and investigate the clinicopathological features and outcomes. METHODS AND RESULTS: Tissues from a total of 477 RCC patients in China were embedded into tissue microarrays for immunostaining...
February 15, 2017: Histopathology
https://www.readbyqxmd.com/read/28197727/perioperative-morbidity-oncological-outcomes-and-predictors-of-pt3a-upstaging-for-patients-undergoing-partial-nephrectomy-for-ct1-tumors
#17
Pascal Mouracade, Onder Kara, Julien Dagenais, M J Maurice, R J Nelson, Ercan Malkoc, J H Kaouk
OBJECTIVES: To evaluate perioperative morbidity, oncological outcome and predictors of pT3a upstaging after partial nephrectomy (PN). MATERIALS AND METHODS: Retrospective study of 1042 patients who underwent PN for cT1N0M0 renal cell carcinoma between 2007 and 2015. A total of 113 cT1 patients were upstaged to pT3a, while 929 were staged as pT1. Demographic, perioperative and pathological variables were reviewed. We compared the clinico-pathological characteristics, perioperative morbidity and oncological outcomes between pT3a and pT1 groups...
February 14, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28193302/outcomes-of-transoral-laser-microsurgical-management-of-t1b-stage-glottic-cancer
#18
J A Song, M H Rigby, J Trites, R D Hart, S M Taylor
OBJECTIVE: This study aimed to evaluate the oncological and voice outcomes of transoral laser microsurgery for tumour stage T1b stage glottic cancer patients. METHODS: A prospective cohort study in a tertiary care head and neck cancer centre included tumour-node-metastasis stage T1bN0M0 glottic cancer patients scheduled to undergo transoral laser microsurgery from January 2002 until June 2014. Kaplan-Meier five-year analyses of local control, overall survival, disease-specific survival and laryngeal preservation were performed...
February 14, 2017: Journal of Laryngology and Otology
https://www.readbyqxmd.com/read/28192244/prognostic-and-clinical-significance-of-claudin-1-in-colorectal-cancer-a-systemic-review-and-meta-analysis
#19
REVIEW
Lu Jiang, Long Yang, He Huang, Bai-Ying Liu, Guo Zu
BACKGROUND: The current reports on the association of claudin-1 expression with colorectal cancer (CRC) result were controversial. Thus, we conducted a meta-analysis to assess the correlation between claudin-1 expression and the clinical parameters and assess the prognostic value of claudin-1 in CRC. METHODS: Systematic searches on PubMed, Embase, Elsevier, CNKI (China National Knowledge Infrastructure), Wanfang data and Cochrane Library prior to August 2016 were performed...
February 10, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28191808/chemoradiation-for-organ-preservation-in-the-treatment-of-muscle-invasive-bladder-cancer-our-institutional-experience
#20
Sweety Gupta, Sudarsan De, Nitin Leekha, Shailesh Chand Sahay, Prekshi Chaudary, Shashank Srinivasan, Malay Nandy
AIM: To assess outcome of chemoradiotherapy for organ preservation in muscle invasive bladder cancer. MATERIAL AND METHODS: 41 patients treated between January 2010 to January 2015 were evaluated in the present study. All patients T staged ranging from cT2-T4a and had undergone maximal transurethral resection of bladder tumour (TURBT). After maximum bladder tumour resection patients were treated with Radiotherapy with or without concurrent chemotherapy. 8 weeks after completion of treatment response was assessed by check cystoscopy, urine cytology and CECT scan Abdomen...
September 2016: Gulf Journal of Oncology
keyword
keyword
22556
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"